Join
Live feed
·
PRReleasevia Quantisnow
Kyverna Therapeutics Inc. logo

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

ByQuantisnow·Wall Street's wire, on your screen.
KYTX· Kyverna Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KYTX (Kyverna Therapeutics Inc.) and more on Quantisnow.